4. Pathological diagnosis and tumor markers

Tumori

Volumn 96, Issue 5, 2010, Pages 810-816

  Milione, Massimo ^a   Seregni, Ettore ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMPHIPHYSIN; CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN A; KI 67 ANTIGEN; NEURON SPECIFIC ENOLASE; TUMOR MARKER; CHGA PROTEIN, HUMAN; ENOLASE;

CANCER DIAGNOSIS; CANCER GRADING; CONFERENCE PAPER; DISTANT METASTASIS; ENDOCRINE CELL; HUMAN; NEUROENDOCRINE TUMOR; PROGNOSIS; SENSITIVITY ANALYSIS; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; TUMOR VOLUME; ARTICLE; BLOOD; CANCER OF UNKNOWN PRIMARY SITE; CELL DIFFERENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; PATHOLOGY; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; URINE;

CARCINOEMBRYONIC ANTIGEN; CELL DIFFERENTIATION; CHROMOGRANIN A; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROXYINDOLEACETIC ACID; NEOPLASMS, UNKNOWN PRIMARY; NEUROENDOCRINE TUMORS; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 78650503205     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600533     Document Type: Conference Paper

References (21)

1. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, Rindi G, Solcia E: Prognostic criteria in nonfunctioning pancreatic endocrine tumors. Virchows Arch, 429: 323-333, 1996. (Pubitemid 26421392)
2. Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G, Pesci A, Baron A, Lissandrini D, Rindi G, Grigolato P, Pederzoli P, Scarpa A: High resolution allelotype of non-functional endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res, 61: 285-292, 2001.
3. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, Iacono C, Serio G, Zamboni G: Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin section i san independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Human Pathol, 27: 1123-1134, 1996.
4. Capurso G, Lattimore S, Crnogorac-Jurcevic T, Panzuto F, Milione M, Bhakta V, Campanini N, Swift SM, Bordi C, Delle Fave G, Lemoine NR: Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer, 13: 541-558, 2006. (Pubitemid 43886676)
5. Zamboni G, Bonetti F, Scarpa A, Pelosi G, Doglioni C, Iannucci A, Castelli P, Balercia G, Aldovini D, Bellomi A, Iacono C, Serio G, Mariuzzi GM: Expression of progesterone receptors in solid-cystic tumour of the pancreas: a clinicopathological and immunohistochemical study of ten cases. Virchows Archiv A Pathol Anat, 423: 425-431, 1993.
6. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M: Chromogranin A-Biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol, 2010, in press.
7. Feldman JM: Carcinoid tumors and syndrome. Semin Oncol, 14: 237-246, 1987.
8. Wolfe MM, Jensen RT: Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med, 317: 1200-1209, 1987. (Pubitemid 17150333)
9. Vinik AI, Gonin J, England BJ, Jackson T, McLeod MK: Plasma substance-P in neuroendocrine tumors and idiopathic flushing: the value of pentagastrin stimulation tests and the effects of somatostatin analog. J Clin Endocrinol Metabol, 70: 1702-1709, 1990.
10. Danforth DN Jr., Gorden P, Brennan MF: Metastatic insulinsecreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery, 96:1027-1037, 1984.
11. nd ed. Heidelberg, World Health Organization, 2000.
12. Taupenot L, Harper K, O'Connor D: The Chromogranin-secretogranin Family. N Engl J Med, 348: 1134-1149, 2003.
13. Shooshtarizadeh P, Zhang D, Chich JF, Gasnier C, Schneider F, Haïkel Y, Aunis D, Metz-Boutigue MH: The antimicrobial peptides derived from chromogranin/secretogranin family, new actors of innate immunity. Regul Pept, 2009, in press.
14. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E, Bombardieri E: Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer, 86: 858-865, 1999.
15. 177Lu]DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging, 54: 84-91, 2010.
16. Welin S, Stridsberg M, Cunningham J, Grandberg D, Skogseid B, Oberg K, Eiksson B, Janson ET: Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology, 89: 302-307, 2009.
17. Massironi S, Conte D, Sciola V, Spampatti MP, Ciafardini C, Valenti L, Rossi RE, Seracchi M: Plasma chromogranin A response to otcreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol, 2010, in press.
18. O'Connor DT, Pandlan MR, Cariton E, Cervenka JH, Hslao RJ: Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem, 35: 1631-1637, 1989. (Pubitemid 19212423)
19. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, Tomassetti P: Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol, 25: 1967-1973, 2007.
20. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F: Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol, 150: 299-303, 2004. (Pubitemid 38443779)
21. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, Parrinello G, Corti A: Chromogranin A in heart failure: a novel neurohumoral factor and a predictor for mortality. Eur Heart J, 23: 926-927, 2002.